CompanyTOVXNYSERockville, MD

Theriva Biologics, Inc.

Theriva Biologics develops oncolytic adenoviruses for cancer treatment.

SEC EDGAR ClinicalTrials.gov therivabio.com

DEF 14AAug 21Latest SEC filing, period to Sep 30

Aug 11Latest story

August 2026

Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancer

Aug 11Quarterly updateTheriva Biologics, Inc.

Theriva doses first patient in VIRAGE2 trial testing repeat VCN-01 dosing in pancreatic cancer

Aug 6Clinical readoutTheriva Biologics, Inc.

Theriva stockholders approve stock plan increase, other proposals at annual meeting

Aug 4PeopleTheriva Biologics, Inc.

July 2026

Theriva gets Spanish authorization for VIRAGE2 trial of VCN-01 in pancreatic cancer

Jul 7Clinical readoutTheriva Biologics, Inc.